Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth (NASDAQ:CSTL)
Earnings Call Insights: Castle Biosciences (CSTL) Q2 2026 Management View "What a great quarter." (Founder, CEO, President & Director Derek ...
